Definium Therapeutics, Inc. (DFTX) Institutional Ownership

Ownership Summary

Definium Therapeutics, Inc. (NASDAQ:DFTX) has 243 institutional investors that have filed 13F reports for the period ending March 2026.

• These investors collectively held 71.7% of Definium Therapeutics's outstanding shares in March 2026, up from 12.2% in December 2025.
• They increased total shares held in Definium Therapeutics by 614.8% from the prior quarter, while the number of investors in DFTX stayed flat year over year.
• Of these 243 holders, 238 added to their stakes in Definium Therapeutics, 4 trimmed positions, and 1 made no changes.
• Altogether, these fund groups held 77.97Mn shares in DFTX by March 2026, up by 67.06Mn shares quarter on quarter, and with no net change year over year.
• As of March 31, 2026, the biggest holder of Definium Therapeutics is BlackRock, Inc. at 8.48Mn shares, representing 7.79% of shares outstanding.
• The most significant purchases of DFTX for the quarter ending March 2026 came from BlackRock, Inc. (8.48Mn), Avoro Capital Advisors LLC (5.0Mn), Janus Henderson Group Plc (3.59Mn), Deep Track Capital, LP (3.0Mn), GEODE CAPITAL MANAGEMENT, LLC (2.5Mn).
• The largest sales of DFTX for the quarter ending March 2026 came from MARSHALL WACE, LLP (1.77Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (625.31K), AWM Investment Company, Inc. (313.77K), Sankala Group LLC (250).
• Definium Therapeutics's 10 largest shareholders as of March 2026 include BlackRock, Inc. (8.48Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (5.91Mn), Avoro Capital Advisors LLC (5.0Mn), Janus Henderson Group Plc (3.59Mn), Deep Track Capital, LP (3.0Mn), GEODE CAPITAL MANAGEMENT, LLC (2.5Mn), State Street Corp (2.47Mn), Octagon Capital Advisors LP (2.44Mn), Commodore Capital LP (2.0Mn), FMR LLC (1.81Mn) per Business Quant data.